Edgewood Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Edgewood Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,500	Closed	-$918K	–	84
2016 Q4	$918K	Sell	2,500 -1,340	-35%	-$510K	0.01%	46
2016 Q3	$1.54M	Buy	3,840 +1,340	+54%	+$538K	0.01%	41
2016 Q2	$873K	Hold	2,500	–	–	0.01%	43
2016 Q1	$901K	Hold	2,500	–	–	0.01%	42
2015 Q4	$1.36M	Hold	2,500	–	–	0.01%	43
2015 Q3	$1.16M	Hold	2,500	–	–	0.01%	42
2015 Q2	$1.27M	Hold	2,500	–	–	0.01%	40
2015 Q1	$1.13M	Hold	2,500	–	–	0.01%	44
2014 Q4	$1.03M	Hold	2,500	–	–	0.01%	46
2014 Q3	$901K	Hold	2,500	–	–	0.01%	48
2014 Q2	$706K	Hold	2,500	–	–	0.01%	47
2014 Q1	$751K	Hold	2,500	–	–	0.01%	45
2013 Q4	$688K	Hold	2,500	–	–	0.01%	47
2013 Q3	$782K	Buy	+2,500	New	+$658K	0.01%	45

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Edgewood Management's REGN Position: Q1 2017 in Review

Edgewood Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2017, closing a stake of 2,500 shares — an estimated $918K sold.

Edgewood Management first reported a position in REGN in Q3 2013 and held it in 14 quarters. The position peaked at $1.54M in Q3 2016. 579 funds tracked by Wall St. Rank hold REGN as of Q1 2017.

Edgewood Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Edgewood Management sold 2,500 Regeneron Pharmaceuticals shares in Q1 2017, an estimated $918K.
Edgewood Management first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 14 quarters.
Edgewood Management's Regeneron Pharmaceuticals position peaked at $1.54M in Q3 2016.
579 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2017.

Based on Edgewood Management's 13F filing for Q1 2017, filed 12 May 2017.